.png){kind=icon}
Return
Artificial intelligence in drug development
.png){kind=icon}
PRE
AI
DOI：10.1038/s41591-024-03434-4.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Drug development is a complex and time-consuming endeavor that traditionally relies on the experience of drug developers and trial-and-error experimentation. The advent of artificial intelligence (AI) technologies, particularly emerging large language models and generative AI, is poised to redefine this paradigm. The integration of AI-driven methodologies into the drug development pipeline has already heralded subtle yet meaningful enhancements in both the efficiency and effectiveness of this process. Here we present an overview of recent advancements in AI applications across the entire drug development workflow, encompassing the identification of disease targets, drug discovery, preclinical and clinical studies, and post-market surveillance. Lastly, we critically examine the prevailing challenges to highlight promising future research directions in AI-augmented drug development.
Keywords:
NOVO MOLECULAR DESIGN
COLORECTAL-CANCER
DEEP
DISCOVERY
PREDICTION
BIOMARKERS
GENERATION
MODEL
Journal
IF:
50
Papers:
1.4W
Citations:
13.4W
Organization
No organization information available
Cited Papers
No cited papers available